Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer.

[1]  M. Minárik,et al.  Multicapillary electrophoresis of unlabeled DNA fragments with high‐sensitive laser‐induced fluorescence detection by counter‐current migration of intercalation dye , 2005, Electrophoresis.

[2]  R. Sylvester,et al.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. , 2004, The Journal of urology.

[3]  C. Cordon-Cardo.  p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Dahse,et al.  P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences. , 2003, Oncology reports.

[5]  A. Gargouri,et al.  A more accurate detection of codon 72 polymorphism and LOH of the TP53 gene. , 2003, Cancer letters.

[6]  R. Knuechel,et al.  Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies , 2002, International journal of cancer.

[7]  R. Knuechel,et al.  Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. , 2002, Cancer research.

[8]  C. Cordon-Cardo,et al.  Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  J. Witjes,et al.  Superficial and metachronous invasive bladder carcinomas are clonally related , 2001, International journal of cancer.

[10]  J. Cheville,et al.  Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract , 2001, Oncogene.

[11]  M. Knowles,et al.  What we could do now: molecular pathology of bladder cancer , 2001, Molecular pathology : MP.

[12]  G. Adessi,et al.  Influence of cigarette smoking on P53 gene mutations in bladder carcinomas. , 2001, Anticancer research.

[13]  D. Newling,et al.  The Use of Valrubicin for the Chemoresection of Superficial Bladder Cancer – A Marker Lesion Study , 2001, European Urology.

[14]  W. Cavenee,et al.  Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. , 2001, International journal of oncology.

[15]  T. Habuchi,et al.  Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. , 2001, The Journal of urology.

[16]  H. Huland,et al.  Relevance of p53 Gene Alterations for Tumor Recurrence in Patients with Superficial Transitional Cell Carcinoma of the Bladder , 2001, European Urology.

[17]  F. Tsai,et al.  Distributions of p53 codon 72 polymorphism in bladder cancer – proline form is prominent in invasive tumor , 2000, Urological Research.

[18]  Dirk Zaak,et al.  Clonality and Genetic Divergence in Multifocal Low-Grade Superficial Urothelial Carcinoma as Determined by Chromosome 9 and p53 Deletion Analysis , 2000, Laboratory Investigation.

[19]  C Béroud,et al.  p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis , 2000, Human mutation.

[20]  L. Cannizzaro,et al.  Identical clonal origin of synchronous and metachronous low-grade, noninvasive papillary transitional cell carcinomas of the urinary tract. , 1999, Human pathology.

[21]  Knowles,et al.  The genetics of transitional cell carcinoma: progress and potential clinical application , 1999, BJU international.

[22]  L. Sobin,et al.  Histological Typing of Urinary Bladder Tumours , 1999, International Histological Classification of Tumours.

[23]  A. Poustka,et al.  Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours. , 1998, British Journal of Cancer.

[24]  Peter A. Jones,et al.  p53 and treatment of bladder cancer , 1997, Nature.

[25]  L. Kiemeney,et al.  The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. , 1993, British Journal of Cancer.

[26]  A. Harris,et al.  Bladder cancer--field versus clonal origin. , 1992, The New England journal of medicine.

[27]  J. Barrett,et al.  An Alu polymorphism intragenic to the TP53 gene. , 1991, Nucleic acids research.

[28]  D. Carbone,et al.  Polymorphism at codon 213 within the p53 gene. , 1991, Oncogene.

[29]  J. Yagüe,et al.  AccII polymorphism of the p53 gene. , 1990, Nucleic acids research.

[30]  N. Mccormick.  A report on the survival of the patients treated for cancer from 1935 to 1947 inclusive. , 1953, Canadian Medical Association journal.

[31]  K. Williamson,et al.  Oligoclonality in bladder cancer: the implication for molecular therapies. , 2004, The Journal of urology.

[32]  A Semjonow,et al.  Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. , 2001, Cancer research.